Last update 08 May 2025

NBTX-001

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
NMDA receptor
Action
antagonists
Mechanism
NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)
Therapeutic Areas
Other Diseases
Active Indication
Panic DisorderObsessive-Compulsive Disorder
Inactive Indication
Alzheimer DiseaseAnxiety DisordersAutism Spectrum Disorder+ [3]
Originator Organization
McLean Hospital, Inc.McLean Hospital, Inc.
Active Organization
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with NBTX-001
NCT03635827
/ Unknown statusPhase 2/3
A Double-Blind, Randomized, Placebo-Controlled Trial of Xenon Inhalation for Treatment of Patients With Posttraumatic Stress Disorder
NCT04097080
/ Unknown statusPhase 1
Comparative Controlled Study of Analgesic, Antiasthenic and Anti-Anxiety Effects of Xenon in Patients With Parkinson's Disease
100 Clinical Results associated with NBTX-001
Login to view more data
100 Translational Medicine associated with NBTX-001
Login to view more data
100 Patents (Medical) associated with NBTX-001
Login to view more data
100 Deals associated with NBTX-001
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Stress Disorders, Post-TraumaticPhase 2-
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
01 Jun 2021
Anxiety DisordersPhase 2
Russia
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
15 Dec 2019
Parkinson DiseasePhase 2
Russia
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
15 Dec 2019
Autism Spectrum DisorderPhase 2
United States
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
09 Apr 2018
Irritable Bowel SyndromePhase 2
United States
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
12 Mar 2018
Alzheimer DiseasePhase 2
United States
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
07 Mar 2018
Panic DisorderPhase 1
Russia
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
-
Obsessive-Compulsive DisorderPreclinical
United States
Nobilis Therapeutics, Inc.Nobilis Therapeutics, Inc.
24 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free